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Sibutramine: Balancing weight loss benefit
and possible cardiovascular riskSibutramine is a tertiary amine, initially developed as
antidepressant, which inhibits serotonin, norepinephrine
and, to a lesser extent, dopamine re-uptake, without
presenting monoamine release activity [1,2]. Sibutramine
is rapidly converted into two metabolites, which are 100-
fold more powerful than the parent compound [3]. Their
half-life is about 14e16 h with a peak concentration after
3e4 h and a plateau from 3 to 7 h [4].
Sibutramine induces weight loss by reducing food intake,
due to hypophagic effect mediated by central b1, a1, and
5-HT2A/2B/2C receptors [5]. The increase in sympathetic ac-
tivity due to sibutramine administration causes an increase
in b3-mediated energy expenditure [6,7], though this effect
needs confirmation in humans [8]. Its effect is dose
dependent [9]. Trials conducted with 10, 15 or 20 mg of
oral sibutramine demonstrated significant progressive
improvement in weight reduction at higher doses of the
drug, when associated with low-calories diet. Nevertheless,
the highest dose used in clinical trials, i.e. 20 mg, has not
been approved for clinical use. Therapy begins with
a dose of 10 mg/OD that will be increased to 15 mg after
two weeks. The recommended dose is 15 mg/OD [10].Weight loss
Compared with placebo, sibutramine increases significantly
the number of patients who reach a weight loss > 5% in
almost all trials [8,10e20]. Patients achieve the most signif-
icant weight loss during the first three months of therapy,
but sibutramine reduces the probability of regaining weight
in long-term therapy in both continuous and intermittent
administration [14].
In a subgroup of the STORM study [21], an abdominal CT
scan performed after six months of therapy, demonstrated
that sibutramine caused an 18% reduction total abdominal
fat by reducing both subcutaneous fat (17%) and total vis-
ceral fat (22%) with a consequent significant increase in sub-
cutaneous-to-visceral fat ratio (p< 0.04). Kamel et al. [22]0939-4753/$ - see front matter ª 2008 Elsevier B.V. All rights reserved
doi:10.1016/j.numecd.2008.03.008estimated changes in intra-abdominal adipose tissue by
magnetic resonance imaging during sibutramine 10 mg/day
combined with a low-calorie diet: after six months of treat-
ment, the decrease in intra-abdominal fat was greater than
the decrease in subcutaneous adipose tissue (p< 0.01), both
significantly correlated with reduction of weight and BMI.
Similarly to other appetite-suppressant drugs, however,
therapy discontinuation causes weight regain, despite this
rebound might be less intense in the short-term, due to
possible effects of the drug on energy expenditure [1,6,7]
or because of a persistent anorectic effect, possibly attrib-
utable to a lack of decrease in plasma leptin concentration
[23]. This possibility, however, was not confirmed in other
studies. During sibutramine therapy, Valsamakis et al. [24]
demonstrated a decrease in serum leptin as well as in C-
reactive protein (CRP) and resistin while adiponectin levels
increased. Extended reviews on beneficial metabolic
effects of sibutramine are available [25].
Asamedication reducingabdominal fat, sibutraminemight
be indicated in abdominal obesity and, therefore, the meta-
bolic syndrome. However, there is some concern about the
complexity of sibutramine effects, especially on the cardio-
vascular system, which has blunted wider use of this drug.
Sympathomimetic-mediated cardiovascular
side effects
Similarly to, but more potently than other appetite-suppres-
sant drugs, sibutramine inhibits Kþ voltage-gate channels of
myocytes [26]. This effect on Kþ channels appears when the
channels are already open, similarly to what has been
described with fluoxetine. Thus, as with fluoxetine, but in
contrast with other inhibitors of serotonin reuptake used
as appetite-suppressant drugs, sibutramine does not in-
crease pulmonary artery pressure [27]. However, in
contrast with fluoxetine, sibutramine tends to increase
systemic pressure and heart rate, both effects attributable
to other peripheral actions on sympathetic system..
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20 mg/OD in those failing to lose weight, the two-year
STORM trial [12] observed a 4.1-bpm increase in heart
rate, 1 mmHg increase in systolic blood pressure and 3
mmHg in diastolic blood pressure, despite the reduction
of body weight, expected to decrease blood pressure and
heart rate. In contrast with this finding, in the same study,
participants on placebo exhibited decreased blood pressure
and heart rate that was in fact associated with diet-related
weight loss. Apparently contrasting results were obtained
in another trial comparing continuous and intermittent
therapy with sibutramine 15 mg [14]. In this study, both
administration regimens did not yield significant change in
blood pressure as compared to a control group, possibly
due to the shorter follow-up (44 weeks versus two years
in the STORM) but also to the absence of patients treated
with higher dose of the drug. In our six-month study [17],
using 10 mg/OD, blood pressure decreased with decreasing
body weight associated with the sibutramine group, al-
though heart rate increased.
In another study [28] 224 adults were assigned to four
intervention groups: lifestyle modification, sibutramine,
combination of both lifestyle modification and sibutr-
amine, and sibutramine with brief lifestyle modification
counseling. After one year, the combination of lifestyle
modification and sibutramine gave the best results in
terms of weight loss, with a statistically significant de-
crease in triglycerides, blood glucose, insulin, LDL
cholesterol and a statistically significant increase in HDL-
cholesterol. The combination also reduced systolic blood
pressure by 4.5 mmHg, which was, however, substantially
less than obtained with the sole lifestyle modifications
(8.5 mmHg), despite the latter intervention was less ef-
fective in reducing weight. Diastolic blood pressure was
reduced only with lifestyle modification (2.2 mmHg),
whereas it was virtually unchanged in the group with com-
bined intervention (þ0.5 mmHg). Sibutramine also tended
to be constantly associated with increased heart rate at
the end of the trial. Obese adolescents have also been
studied [29]. Sibutramine therapy was associated with
greater weight reduction and improvement in plasma glu-
cose, cholesterol, triglycerides, but also with significant in-
crease in heart rate with unchanged blood pressure. Also in
this case, however, there was a substantial discrepancy be-
tween the level of body weight reduction obtained with
sibutramine and the effect on blood pressure and heart
rate, as compared to the group on lifestyle intervention.
The effect of sibutramine-induced weight loss has been
evaluated also on obstructive sleep apnoea (OSA). The
significant weight loss at six months (8.3 4.7 kg, p <
0.0001) led to significant amelioration of symptoms and im-
provement of objective markers of OSA (Respiratory Distur-
bance Index (RDI)). There was no change in blood pressure,
but resting heart rate increased. The authors highlighted
that, thoughmostof the improvementwas likelydue toweight
loss, an independent effect of the drug could not beexcluded,
possibly due to direct neuropharmacological action [30].
Overall taken, these findings suggest that sibutramine
has a sympathomimetic effect on both blood pressure and
heart rate, and that this effect can be offset, though not
completely eliminated, if body weight reduction is signif-
icant [31,32].Is it possible to antagonize cardiovascular
side-effect?
To minimize undesired cardiovascular effects, a program of
aerobic physical exercise [33] or combination of sibutr-
amine with other medications might be suggested. A combi-
nation of sibutramine with ACE inhibitors, has been
proposed especially in diabetic patients [11]. In a small
group of healthy volunteers, Birkenfeld et al. [34] showed
that the sibutramine-induced increase in blood pressure
and heart rate can be abolished by metoprolol (25 mg). In
this study, despite the increase in blood pressure and heart
rate, sibutramine also caused decrease in plasma level of
norepinephrine and less response to hand grip and cold
pressor test. This finding has been interpreted as a conse-
quence of a possible central clonidine-like activity [34],
at least partially offsetting the peripheral effect. This clo-
nidine-like activity might be maximal in obese patients with
arterial hypertension, ultimately leading to blood pressure
reduction [34]. Similar findings were obtained by Jordan et
al. [35], who analyzed data obtained in two clinical trials.
This hypothesis has not been confirmed in other studies in
obese subjects with arterial hypertension in whom sibutr-
amine administration increased both blood pressure and
heart rate, despite its centrally mediated effect [36].
Recently sibutramine therapy has also been associated
with favourable effect on endothelial function [37]. There
is no information on the potential impact of associated
b-blocker therapy on the postulated sibutramine-induced
b3-mediated increase of energy expenditure. Recently
a clinical trial, comparing different antihypertensive regi-
mens during sibutramine administration showed that the
combination of metoprolol plus hydrochlorothiazide
reduces the beneficial effects of sibutramine on weight
loss and metabolic parameters if compared with treatment
including ACE inhibitors and calcium-channel-blockers [38].
Potential cardiovascular benefits
Paralleling reduction of body weight, and opposing to the
reported side effects, sibutramine therapy is also associ-
ated with reduction of left ventricular (LV) mass (M ),
a potent marker of cardiovascular outcome [39,40]. Zannad
et al. [16] studied 185 obese patients divided into three
groups (placebo, 10, and 20 mg sibutramine). Mean changes
of LVM index (LVM/height) were similar in placebo
(3.0 11.9 g/m, nZ 56), sibutramine 10 mg (4.4
 10.7 g/m, nZ 61), and sibutramine 20 mg (4.3
 10.9 g/m, nZ 56), but difference from baseline values
was significant only in the groups treated with sibutramine.
In another randomized placebo-controlled study including
patients with arterial hypertension [17], we showed that
the sibutramine treated group had a significantly greater
decrease in LVM than placebo, due to greater weight loss,
and greater LV mass at baseline, because of a higher
proportion of hypertensive subjects.
The reduction of LVM in our study was substantially
sustained by the greater reduction of LV end-diastolic
diameter (a crude indicator of preload), probably as
a consequence of weight loss related diuresis, a character-
istic also evident in Zannad’s study with the 20 mg dose
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with the weight-loss-dependent slight reduction of blood
pressure, probably facilitated by the baseline blood pres-
sure that was higher than in Zannad’s study. The coinci-
dence with a pronounced weight loss (10%) should also be
considered important, consistent with the evidence that
LV mass substantially decreases when weight loss is
significant [40e42].
These two studies did not show increase in blood pressure
except for Zannad’s sibutramine 20 mg group, an increase,
however, which did not reach statistical significance.
There is also evidence of favourable metabolic changes
associated with sibutramine-induced weight loss, including
decrease in VLDL-cholesterol, triglycerides and uric acid,
increase in HDL-cholesterol and improvement in glycemic
control [13,18,19]. In particular, Fujioka et al. [18] showed
that in type 2 diabetic patients, sibutramine reduced
HbA1c and fasting plasma glucose, in relation to the de-
crease in body weight. Correlation between diabetic control
and changes in body weight was not evident in the placebo
group.Balancing evidence
Obesity should be considered as a major cardiovascular risk
factor [43] tracking hypertension, diabetes, dyslipidemia
and, eventually, the metabolic syndrome. It is associated
with increased LVM, an extraordinarily potent marker of
preclinical cardiovascular disease, predicting 2.5-fold
higher risk of cardiovascular events [39]. Weight reduction
is the first and most important objective to reduce
obesity-associated comorbidities and, therefore, cardiovas-
cular risk.
Unfortunately sibutramine has significant unfavourable
effects on cardiovascular system that should be considered
as potentially offsetting, at least in part, a long-term
benefit. At this time, there is no evidence of improvement
in event-free survival, especially when an efficacious
weight loss is not achieved. In weighting advantages and
disadvantages of therapy with sibutramine, considerations
should be, therefore, developed on both long-term benefits
in high-risk patients and the possibility to combine medi-
cations able to balance sibutramine-induced increase in
blood pressure and heart rate, two very adverse reactions
to the drug administration. Although there are trials that
did not show increase in blood pressure and heart rate,
attention should be paid to the fact that the successful
weight loss achieved in these studies could be expected to
track more substantial blood pressure reduction and de-
crease in heart rate than obtained with sibutramine, as
suggested in other trials without pharmacologic interven-
tion [44] and studies on the reduction of sympathetic drive
tracked by weight loss [45]. Combination of sibutramine
with b-blockers might be promising to antagonize heart
rate increase, but the possible block of b3-receptors might
decrease the effect of sibutramine.
At present, sibutramine is an effective appetite-sup-
pressant drug, reducing body weight, and potentially
affecting positively some, but not all, cardiovascular risk
factors [46]; however, it cannot be prescribed in patients
with high cardiovascular risk, according to licensingrecommendations. The SCOUT study [47] was designed to
verify safety of sibutramine use in high cardiovascular risk
patients, in consideration of the fact that the positive
effect of the drug on metabolic parameters could counter-
balance and overwhelm the increase in sympathetic activ-
ity that might be pharmacologically controlled.
Preliminary data from the 6-week lead-in period of the
SCOUT study [48] confirm previous reports: decrease in
systolic and diastolic blood pressure parallels the reduction
in body weight, but pulse rate is increased (all p< 0.001).
Death occurred in a rate at least comparable to (and
possibly less than) that reported in other studies with
similar populations (HOPE, ASCOTT-LLA).
In the balance between visible benefits and potential
risks of sibutramine treatment, we should consider that
cardiovascular risk might discourage the use of the medi-
cation, but also that reduction of body weight in severe
obesity might be mandatory especially in those patients
with high-risk profile. The results of the SCOUT study will be
extremely relevant to resolve a conundrum that in the
meantime remains to the doctors’ wisdom.
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